VILEVEV MB Urinary Antispetic — Class II drug recall D-1488-2020
Terminated recall by Vilvet Pharmaceuticals Inc., reported 2020-08-12, distributed nationwide. cGMP deviations
| Recall number | D-1488-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Vilvet Pharmaceuticals Inc., Chester Springs, PA, United States |
| Recall initiated | 2020-07-24 |
| Classified | 2020-08-06 |
| Reported by FDA | 2020-08-12 |
| Terminated | 2022-01-21 |
| Distributed | Nationwide (US) |
| Quantity | 1,716 bottles |
| Reason classes | cgmp |
| NDC | 71186-0000-24 |
| Lot numbers | 04/21, 09/20, M823D19-1, M823J18-1, M823J18-2, M823J18-3 |
Product
VILEVEV MB Urinary Antispetic (81.0 mg methenamine, 40.8 mg sodium phosphate monobasic and 10.8 mg methylene blue, 0.12 mg hyoscyamine sulfate and 32.4 mg phenyl salicylate), Rx Only, 90 Tablets per Bottle, Manufactured for: Vilvet Pharmaceuticals, Inc., Chester Springs, PA 19425, NDC 71186-000-24.
Reason for recall
cGMP deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1488-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.